1-17 of 17
Byoung Chul Cho
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

ctDNA Dynamics and Mechanisms of Acquired Resistance in Patients Treated with Osimertinib with or without Bevacizumab from the Randomized Phase II ETOP-BOOSTER Trial

Ross A. Soo, Urania Dafni, Ji-Youn Han, Byoung Chul Cho, Ernest Nadal, Chong Ming Yeo, Enric Carcereny, Javier de Castro, Maria Angeles Sala, Linda Coate, Mariano Provencio, Christian Britschgi, Patrick Vagenknecht, Georgia Dimopoulou, Roswitha Kammler, Stephen P. Finn, Solange Peters, Rolf A. Stahel, for the ETOP 10-16 BOOSTER Collaborators
Journal: Clinical Cancer Research
Clin Cancer Res (2024) 30 (22): 5180–5191.
https://doi.org/10.1158/1078-0432.CCR-24-0932
Published: 15 November 2024
View article titled, ctDNA Dynamics and Mechanisms of Acquired Resistance in Patients Treated with Osimertinib with or without Bevacizumab from the Randomized Phase II ETOP-BOOSTER Trial
Open the PDF for ctDNA Dynamics and Mechanisms of Acquired Resistance in Patients Treated with Osimertinib with or without Bevacizumab from the Randomized Phase II ETOP-BOOSTER Trial in another window
Includes: Supplementary data
Journal Articles

Discovery of a Novel Potent EGFR Inhibitor Against EGFR Activating Mutations and On-Target Resistance in NSCLC

Eun Ji Lee, Seung Yeon Oh, You Won Lee, Ju Young Kim, Min-Je Kim, Tae Ho Kim, Jii Bum Lee, Min Hee Hong, Sun Min Lim, Anke Baum, Lydia Woelflingseder, Harald Engelhardt, Mark Petronczki, Flavio Solca, Mi Ran Yun, Byoung Chul Cho
Journal: Clinical Cancer Research
Clin Cancer Res (2024) 30 (8): 1582–1594.
https://doi.org/10.1158/1078-0432.CCR-23-2951
Published: 15 April 2024
View article titled, Discovery of a Novel Potent EGFR Inhibitor Against EGFR Activating Mutations and On-Target Resistance in NSCLC
Open the PDF for Discovery of a Novel Potent EGFR Inhibitor Against EGFR Activating Mutations and On-Target Resistance in NSCLC in another window
Includes: Supplementary data
Journal Articles

Early Clearance of Plasma Epidermal Growth Factor Receptor Mutations as a Predictor of Outcome on Osimertinib in Advanced Non–Small Cell Lung Cancer; Exploratory Analysis from AURA3 and FLAURA

Jhanelle E. Gray, Myung-Ju Ahn, Geoffrey R. Oxnard, Frances A. Shepherd, Fumio Imamura, Ying Cheng, Isamu Okamoto, Byoung Chul Cho, Meng-Chih Lin, Yi-Long Wu, Margarita Majem, Oliver Gautschi, Michael Boyer, Krishna C. Bulusu, Aleksandra Markovets, J. Carl Barrett, Rachel Hodge, Astrid McKeown, Ryan J. Hartmaier, Juliann Chmielecki, Vassiliki A. Papadimitrakopoulou, Suresh S. Ramalingam
Journal: Clinical Cancer Research
Clin Cancer Res (2023) 29 (17): 3340–3351.
https://doi.org/10.1158/1078-0432.CCR-22-3146
Published: 01 September 2023
View article titled, Early Clearance of Plasma <em>Epidermal Growth Factor Receptor</em> Mutations as a Predictor of Outcome on Osimertinib in Advanced Non–Small Cell Lung Cancer; Exploratory Analysis from AURA3 and FLAURA
Open the PDF for Early Clearance of Plasma <em>Epidermal Growth Factor Receptor</em> Mutations as a Predictor of Outcome on Osimertinib in Advanced Non–Small Cell Lung Cancer; Exploratory Analysis from AURA3 and FLAURA in another window
Includes: Supplementary data
Journal Articles

Preclinical Study of a Biparatopic METxMET Antibody–Drug Conjugate, REGN5093-M114, Overcomes MET-driven Acquired Resistance to EGFR TKIs in EGFR-mutant NSCLC

Seung Yeon Oh, You Won Lee, Eun Ji Lee, Jae Hwan Kim, YoungJoon Park, Seong Gu Heo, Mi Ra Yu, Min Hee Hong, John DaSilva, Christopher Daly, Byoung Chul Cho, Sun Min Lim, Mi Ran Yun
Journal: Clinical Cancer Research
Clin Cancer Res (2023) 29 (1): 221–232.
https://doi.org/10.1158/1078-0432.CCR-22-2180
Published: 04 January 2023
View article titled, Preclinical Study of a Biparatopic METxMET Antibody–Drug Conjugate, REGN5093-M114, Overcomes MET-driven Acquired Resistance to EGFR TKIs in EGFR-mutant NSCLC
Open the PDF for Preclinical Study of a Biparatopic METxMET Antibody–Drug Conjugate, REGN5093-M114, Overcomes MET-driven Acquired Resistance to EGFR TKIs in EGFR-mutant NSCLC in another window
Includes: Supplementary data
Journal Articles

Three-Year Follow-Up and Response–Survival Relationship of Nivolumab in Previously Treated Patients with Advanced Esophageal Squamous Cell Carcinoma (ATTRACTION-3)

Morihito Okada, Ken Kato, Byoung Chul Cho, Masanobu Takahashi, Chen-Yuan Lin, Keisho Chin, Shigenori Kadowaki, Myung-Ju Ahn, Yasuo Hamamoto, Yuichiro Doki, Chueh-Chuan Yen, Yutaro Kubota, Sung-Bae Kim, Chih-Hung Hsu, Eva Holtved, Ioannis Xynos, Yasuhiro Matsumura, Akira Takazawa, Yuko Kitagawa
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (15): 3277–3286.
https://doi.org/10.1158/1078-0432.CCR-21-0985
Published: 02 August 2022
View article titled, Three-Year Follow-Up and Response–Survival Relationship of Nivolumab in Previously Treated Patients with Advanced Esophageal Squamous Cell Carcinoma (ATTRACTION-3)
Open the PDF for Three-Year Follow-Up and Response–Survival Relationship of Nivolumab in Previously Treated Patients with Advanced Esophageal Squamous Cell Carcinoma (ATTRACTION-3) in another window
Includes: Supplementary data
Journal Articles

Correction: Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Patients with NTRK Fusion–Positive Solid Tumors

George D. Demetri, Filippo De Braud, Alexander Drilon, Salvatore Siena, Manish R. Patel, Byoung Chul Cho, Stephen V. Liu, Myung-Ju Ahn, Chao-Hua Chiu, Jessica J. Lin, Koichi Goto, Jeeyun Lee, Lyudmila Bazhenova, Thomas John, Marwan Fakih, Sant P. Chawla, Rafal Dziadziuszko, Takashi Seto, Sebastian Heinzmann, Bethany Pitcher, David Chen, Timothy R. Wilson, Christian Rolfo
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (10): 2196.
https://doi.org/10.1158/1078-0432.CCR-22-1108
Published: 13 May 2022
View article titled, Correction: Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Patients with <em>NTRK</em> Fusion–Positive Solid Tumors
Open the PDF for Correction: Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Patients with <em>NTRK</em> Fusion–Positive Solid Tumors in another window
Journal Articles

Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Patients With NTRK Fusion-Positive Solid Tumors

George D. Demetri, Filippo De Braud, Alexander Drilon, Salvatore Siena, Manish R. Patel, Byoung Chul Cho, Stephen V. Liu, Myung-Ju Ahn, Chao-Hua Chiu, Jessica J. Lin, Koichi Goto, Jeeyun Lee, Lyudmila Bazhenova, Thomas John, Marwan Fakih, Sant P. Chawla, Rafal Dziadziuszko, Takashi Seto, Sebastian Heinzmann, Bethany Pitcher, David Chen, Timothy R. Wilson, Christian Rolfo
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (7): 1302–1312.
https://doi.org/10.1158/1078-0432.CCR-21-3597
Published: 01 April 2022
View article titled, Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Patients With <em>NTRK</em> Fusion-Positive Solid Tumors
Open the PDF for Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Patients With <em>NTRK</em> Fusion-Positive Solid Tumors in another window
Includes: Supplementary data
Journal Articles

Tepotinib Efficacy and Safety in Patients with MET Exon 14 Skipping NSCLC: Outcomes in Patient Subgroups from the VISION Study with Relevance for Clinical Practice

Xiuning Le, Hiroshi Sakai, Enriqueta Felip, Remi Veillon, Marina Chiara Garassino, Jo Raskin, Alexis B. Cortot, Santiago Viteri, Julien Mazieres, Egbert F. Smit, Michael Thomas, Wade T. Iams, Byoung Chul Cho, Hye Ryun Kim, James Chih-Hsin Yang, Yuh-Min Chen, Jyoti D. Patel, Christine M. Bestvina, Keunchil Park, Frank Griesinger, Melissa Johnson, Maya Gottfried, Christian Britschgi, John Heymach, Elif Sikoglu, Karin Berghoff, Karl-Maria Schumacher, Rolf Bruns, Gordon Otto, Paul K. Paik
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (6): 1117–1126.
https://doi.org/10.1158/1078-0432.CCR-21-2733
Published: 15 March 2022
View article titled, Tepotinib Efficacy and Safety in Patients with <em>MET</em> Exon 14 Skipping NSCLC: Outcomes in Patient Subgroups from the VISION Study with Relevance for Clinical Practice
Open the PDF for Tepotinib Efficacy and Safety in Patients with <em>MET</em> Exon 14 Skipping NSCLC: Outcomes in Patient Subgroups from the VISION Study with Relevance for Clinical Practice in another window
Includes: Supplementary data
Journal Articles

Intracranial Efficacy of Selpercatinib in RET Fusion-Positive Non–Small Cell Lung Cancers on the LIBRETTO-001 Trial

Vivek Subbiah, Justin F. Gainor, Geoffrey R. Oxnard, Daniel S.W. Tan, Dwight H. Owen, Byoung Chul Cho, Herbert H. Loong, Caroline E. McCoach, Jared Weiss, Yu Jung Kim, Lyudmila Bazhenova, Keunchil Park, Haruko Daga, Benjamin Besse, Oliver Gautschi, Christian Rolfo, Edward Y. Zhu, Jennifer F. Kherani, Xin Huang, Suhyun Kang, Alexander Drilon
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (15): 4160–4167.
https://doi.org/10.1158/1078-0432.CCR-21-0800
Published: 01 August 2021
View article titled, Intracranial Efficacy of Selpercatinib in <em>RET</em> Fusion-Positive Non–Small Cell Lung Cancers on the LIBRETTO-001 Trial
Open the PDF for Intracranial Efficacy of Selpercatinib in <em>RET</em> Fusion-Positive Non–Small Cell Lung Cancers on the LIBRETTO-001 Trial in another window
Includes: Supplementary data
Journal Articles

Modeling Clinical Responses to Targeted Therapies by Patient-Derived Organoids of Advanced Lung Adenocarcinoma

Seok-Young Kim, Sang-Min Kim, Sumin Lim, Ji Yeon Lee, Su-Jin Choi, San-Duk Yang, Mi Ran Yun, Chang Gon Kim, Seo Rin Gu, Chaewon Park, A-Young Park, Sun Min Lim, Seong Gu Heo, HyunKi Kim, Byoung Chul Cho
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (15): 4397–4409.
https://doi.org/10.1158/1078-0432.CCR-20-5026
Published: 01 August 2021
View article titled, Modeling Clinical Responses to Targeted Therapies by Patient-Derived Organoids of Advanced Lung Adenocarcinoma
Open the PDF for Modeling Clinical Responses to Targeted Therapies by Patient-Derived Organoids of Advanced Lung Adenocarcinoma in another window
Includes: Supplementary data
Journal Articles

Repotrectinib Exhibits Potent Antitumor Activity in Treatment-Naïve and Solvent-Front–Mutant ROS1-Rearranged Non–Small Cell Lung Cancer

Mi Ran Yun, Dong Hwi Kim, Seok-Young Kim, Hyeong-Seok Joo, You Won Lee, Hun Mi Choi, Chae Won Park, Seong Gu Heo, Han Na Kang, Sung Sook Lee, Adam J. Schoenfeld, Alexander Drilon, Seok-Gu Kang, Hyo Sup Shim, Min Hee Hong, J. Jean Cui, Hye Ryun Kim, Byoung Chul Cho
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2020) 26 (13): 3287–3295.
https://doi.org/10.1158/1078-0432.CCR-19-2777
Published: 01 July 2020
View article titled, Repotrectinib Exhibits Potent Antitumor Activity in Treatment-Naïve and Solvent-Front–Mutant ROS1-Rearranged Non–Small Cell Lung Cancer
Open the PDF for Repotrectinib Exhibits Potent Antitumor Activity in Treatment-Naïve and Solvent-Front–Mutant ROS1-Rearranged Non–Small Cell Lung Cancer in another window
Includes: Supplementary data
Journal Articles

YH25448, an Irreversible EGFR-TKI with Potent Intracranial Activity in EGFR Mutant Non–Small Cell Lung Cancer

Jiyeon Yun, Min Hee Hong, Seok-Young Kim, Chae-Won Park, Soyoung Kim, Mi Ran Yun, Han Na Kang, Kyoung-Ho Pyo, Sung Sook Lee, Jong Sung Koh, Ho-Juhn Song, Dong Kyun Kim, Young-Sung Lee, Se-Woong Oh, Soongyu Choi, Hye Ryun Kim, Byoung Chul Cho
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2019) 25 (8): 2575–2587.
https://doi.org/10.1158/1078-0432.CCR-18-2906
Published: 15 April 2019
View article titled, YH25448, an Irreversible EGFR-TKI with Potent Intracranial Activity in EGFR Mutant Non–Small Cell Lung Cancer
Open the PDF for YH25448, an Irreversible EGFR-TKI with Potent Intracranial Activity in EGFR Mutant Non–Small Cell Lung Cancer in another window
Includes: Supplementary data
Journal Articles

Phase II Clinical and Exploratory Biomarker Study of Dacomitinib in Patients with Recurrent and/or Metastatic Squamous Cell Carcinoma of Head and Neck

Han Sang Kim, Hyeong Ju Kwon, Inkyung Jung, Mi Ran Yun, Myung-Ju Ahn, Byung Woog Kang, Jong-Mu Sun, Sung Bae Kim, Dok-Hyun Yoon, Keon Uk Park, Se-Hoon Lee, Yoon Woo Koh, Se Hun Kim, Eun Chang Choi, Dong Hoe Koo, Jin Hee Sohn, Bomi Kim, Nak-Jung Kwon, Hwan Jung Yun, Min Goo Lee, Ji Hyun Lee, Tae-Min Kim, Hye Ryun Kim, Joo Hang Kim, Soonmyung Paik, Byoung Chul Cho
Journal: Clinical Cancer Research
Clin Cancer Res (2015) 21 (3): 544–552.
https://doi.org/10.1158/1078-0432.CCR-14-1756
Published: 01 February 2015
View article titled, Phase II Clinical and Exploratory Biomarker Study of Dacomitinib in Patients with Recurrent and/or Metastatic Squamous Cell Carcinoma of Head and Neck
Open the PDF for Phase II Clinical and Exploratory Biomarker Study of Dacomitinib in Patients with Recurrent and/or Metastatic Squamous Cell Carcinoma of Head and Neck in another window
Includes: Supplementary data
Journal Articles

High EGFR Gene Copy Number and Skin Rash as Predictive Markers for EGFR Tyrosine Kinase Inhibitors in Patients with Advanced Squamous Cell Lung Carcinoma

Youngjoo Lee, Hyo Sup Shim, Moo Suk Park, Joo-Hang Kim, Sang-Jun Ha, Se Hoon Kim, Byoung Chul Cho
Journal: Clinical Cancer Research
Clin Cancer Res (2012) 18 (6): 1760–1768.
https://doi.org/10.1158/1078-0432.CCR-11-2582
Published: 14 March 2012
View article titled, High <em>EGFR</em> Gene Copy Number and Skin Rash as Predictive Markers for EGFR Tyrosine Kinase Inhibitors in Patients with Advanced Squamous Cell Lung Carcinoma
Open the PDF for High <em>EGFR</em> Gene Copy Number and Skin Rash as Predictive Markers for EGFR Tyrosine Kinase Inhibitors in Patients with Advanced Squamous Cell Lung Carcinoma in another window
Journal Articles

Abstract B11: EGFR polymorphism as a predictor of clinical outcome in advanced lung cancer patients treated with EGFR-TKI

Minkyu Jung, Chul Ho Lee, Hyung Soon Park, Ji Hyun Lee, Joo Hang Kim, Young Ae Kang, Se Kyu Kim, Joon Chang, Dae Jun Kim, Byoung Chul Cho
Journal: Clinical Cancer Research
Clin Cancer Res (2012) 18 (3_Supplement): B11.
https://doi.org/10.1158/1078-0432.12AACRIASLC-B11
Published: 01 February 2012
View article titled, Abstract B11: EGFR polymorphism as a predictor of clinical outcome in advanced lung cancer patients treated with EGFR-TKI
Open the PDF for Abstract B11: EGFR polymorphism as a predictor of clinical outcome in advanced lung cancer patients treated with EGFR-TKI in another window
Journal Articles

High Tumor Metabolic Activity as Measured by Fluorodeoxyglucose Positron Emission Tomography Is Associated with Poor Prognosis in Limited and Extensive Stage Small-Cell Lung Cancer

Young Joo Lee, Arthur Cho, Byoung Chul Cho, Mijin Yun, Se Kyu Kim, Joon Chang, Jin Wook Moon, In Kyu Park, Hye Jin Choi, Joo-Hang Kim
Journal: Clinical Cancer Research
Clin Cancer Res (2009) 15 (7): 2426–2432.
https://doi.org/10.1158/1078-0432.CCR-08-2258
Published: 01 April 2009
View article titled, High Tumor Metabolic Activity as Measured by Fluorodeoxyglucose Positron Emission Tomography Is Associated with Poor Prognosis in Limited and Extensive Stage Small-Cell Lung Cancer
Open the PDF for High Tumor Metabolic Activity as Measured by Fluorodeoxyglucose Positron Emission Tomography Is Associated with Poor Prognosis in Limited and Extensive Stage Small-Cell Lung Cancer in another window
Journal Articles

Enhanced Antitumor Effect of Oncolytic Adenovirus Expressing Interleukin-12 and B7-1 in an Immunocompetent Murine Model

Young-Sook Lee, Joo-Hang Kim, Kyung-Ju Choi, Il-Kyu Choi, Hoguen Kim, Sungae Cho, Byoung Chul Cho, Chae-Ok Yun
Journal: Clinical Cancer Research
Clin Cancer Res (2006) 12 (19): 5859–5868.
https://doi.org/10.1158/1078-0432.CCR-06-0935
Published: 04 October 2006
View article titled, Enhanced Antitumor Effect of Oncolytic Adenovirus Expressing Interleukin-12 and B7-1 in an Immunocompetent Murine Model
Open the PDF for Enhanced Antitumor Effect of Oncolytic Adenovirus Expressing Interleukin-12 and B7-1 in an Immunocompetent Murine Model in another window